Cite
HARVARD Citation
Pouillon, L. et al. (2018). Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Alimentary pharmacology & therapeutics. 48 (5), pp. 574-575. [Online].